2 completed, 1 terminated. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow ERYtech Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) eryaspase (L-asparaginase encapsulated in red blood cells), Gemcitabine, Carboplatin - Triple Negative Breast Cancer | Phase 2 / Phase 3 | Terminated | ERYtech Pharma | 27 | 2019-06-13 | 2022-08-01 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin - Pancreatic Adenocarcinoma | Phase 3 | Completed | ERYtech Pharma | 512 | 2018-09-15 | 2022-10-18 |
| GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia GRASPA, L-asparaginase - Acute Lymphoblastic Leukemia, in Relapse | Phase 2 / Phase 3 | Completed | ERYtech Pharma | 85 | 2009-12-01 | 2022-02-02 |
Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
Asparaginase (2) · Gemcitabine (2) · eryaspase (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Erythrocyte Count (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Paclitaxel (1) · irinotecan sucrosofate (1)
Belgium (2) · France (2) · Hungary (1) · Spain (1) · United Kingdom (1) · United States (1)
Manuel Hidalgo, MD, PhD (1) · Pascal Hammel, MD, PhD (1) · Yves Bertand, MD (1)